We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $67.49, moving -0.97% from the previous trading session. This move lagged the S&P 500's daily gain of 0.18%. Meanwhile, the Dow gained 0.14%, and the Nasdaq, a tech-heavy index, added 0.74%.
Heading into today, shares of the HIV and hepatitis C drugmaker had lost 5.19% over the past month, lagging the Medical sector's loss of 3.85% and outpacing the S&P 500's loss of 6.19% in that time.
Wall Street will be looking for positivity from GILD as it approaches its next earnings report date. This is expected to be February 5, 2019. In that report, analysts expect GILD to post earnings of $1.74 per share. This would mark a year-over-year decline of 2.25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.52 billion, down 7.26% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.93 per share and revenue of $21.85 billion, which would represent changes of -21.61% and -16.31%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for GILD. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. GILD is currently sporting a Zacks Rank of #1 (Strong Buy).
In terms of valuation, GILD is currently trading at a Forward P/E ratio of 9.83. Its industry sports an average Forward P/E of 23.26, so we one might conclude that GILD is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 66, putting it in the top 26% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $67.49, moving -0.97% from the previous trading session. This move lagged the S&P 500's daily gain of 0.18%. Meanwhile, the Dow gained 0.14%, and the Nasdaq, a tech-heavy index, added 0.74%.
Heading into today, shares of the HIV and hepatitis C drugmaker had lost 5.19% over the past month, lagging the Medical sector's loss of 3.85% and outpacing the S&P 500's loss of 6.19% in that time.
Wall Street will be looking for positivity from GILD as it approaches its next earnings report date. This is expected to be February 5, 2019. In that report, analysts expect GILD to post earnings of $1.74 per share. This would mark a year-over-year decline of 2.25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.52 billion, down 7.26% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.93 per share and revenue of $21.85 billion, which would represent changes of -21.61% and -16.31%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for GILD. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. GILD is currently sporting a Zacks Rank of #1 (Strong Buy).
In terms of valuation, GILD is currently trading at a Forward P/E ratio of 9.83. Its industry sports an average Forward P/E of 23.26, so we one might conclude that GILD is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 66, putting it in the top 26% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.